Different from the HIV Fusion Inhibitor C34, the Anti-HIV Drug Fuzeon (T-20) Inhibits HIV-1 Entry by Targeting Multiple Sites in gp41 and gp120

This publication has 64 references indexed in Scilit:

• Impact of Mutations in the Coreceptor Binding Site on Human Immunodeficiency Virus Type 1 Fusion, Infection, and Entry Inhibitor Sensitivity
  Journal of Virology, 2004
• Basis for fusion inhibition by peptides: analysis of the heptad repeat regions of the fusion proteins from Nipah and Hendra viruses, newly emergent zoonotic paramyxoviruses
  Biochemical and Biophysical Research Communications, 2004
• Rapid and Automated Fluorescence-Linked Immunosorbent Assay for High-Throughput Screening of Hiv-1 Fusion Inhibitors Targeting gp41
  SLAS Discovery, 2003
• Novel Therapies Based on Mechanisms of HIV-1 Cell Entry
  New England Journal of Medicine, 2003
• The Hydrophobic Pocket Contributes to the Structural Stability of the N-Terminal Coiled Coil of HIV gp41 but Is Not Required for Six-Helix Bundle Formation
  Biochemistry, 2003
• Design of a Protein Surface Antagonist Based on α-Helix Mimicry: Inhibition of gp41 Assembly and Viral Fusion We thank the National Institutes of Health for support of this work and the Deutsche Forschungsgemeinschaft (DFG) for a research fellowship to O.K.
  Angewandte Chemie International Edition in English, 2002
• Two Interaction Modes of the gp41-Derived Peptides with gp41 and Their Correlation with Antimembrane Fusion Activity
  Biochemical and Biophysical Research Communications, 1999
• Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.
  Proceedings of the National Academy of Sciences, 1996
• Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection.
  Proceedings of the National Academy of Sciences, 1994
• A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell Fusion
  AIDS Research and Human Retroviruses, 1993